• ASTRAL-3—GT3 only; Sovaldi + GS-5816 for 12w vs Sovaldi + ribavirin for 24w (i.e. existing GT3 “SoC”); 500 patients; expected completion Dec 2015: http://clinicaltrials.gov/ct2/show/NCT02201953
• ASTRAL-4—All genotypes with cirrhosis; three arms: Sovaldi + GS-5816 for 12w vs Sovaldi + GS-5816 + ribavirin for 12w vs Sovaldi + GS-5816 for 24w; 225 patients; expected completion Nov 2015: http://clinicaltrials.gov/ct2/show/NCT02201901
GILD has aparently thrown in the towel on the idea of seeking approval for 8-week or shorter regimens of Sovaldi + GS-5816.
H/t @lomu_j.
*GS-5816 is an NS5A inhibitor that has better activity against GT3 than Ledipasvir.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.